Circulating fibronectin isoforms predict the degree of fibrosis in chronic hepatitis C

References

• Armstrong GL, Wasley A, Simard EP, McQuillan GM, Kuhnert WL, Alter MJ. The prevalence of hepatitis C virus infection in the United States, 1999 through 2002. Ann Intern Med 2006;144:705–14.
   PubMed Web of Science ®Google Scholar
• Thein HH, Yi Q, Dore GJ, Krahn MD. Estimation of stage-specific fibrosis progression rates in chronic hepatitis C virus infection: a meta-analysis and meta-regression. Hepatology (Baltimore, MD) 2008;48:418–31.
   PubMed Web of Science ®Google Scholar
• Bedossa P, Poynard T. An algorithm for the grading of activity in chronic hepatitis C. The METAVIR Cooperative Study Group. Hepatology 1996;24:289–93.
   PubMed Web of Science ®Google Scholar
• Dienstag JL, McHutchison JG. American Gastroenterological Association technical review on the management of hepatitis C. Gastroenterology 2006;130:231–64; quiz 14–17.
   PubMed Web of Science ®Google Scholar
• Hoofnagle JH, Seeff LB. Peginterferon and ribavirin for chronic hepatitis C. N Engl J Med 2006;355:2444–51.
   PubMed Web of Science ®Google Scholar
• Pawlotsky JM. Pathophysiology of hepatitis C virus infection and related liver disease. Trends Microbiol 2004;12:96–102.
   PubMed Web of Science ®Google Scholar
• Wynn TA. Cellular and molecular mechanisms of fibrosis. J Pathol 2008;214:199–210.
   PubMed Web of Science ®Google Scholar
• Bissell DM. Cell-matrix interaction and hepatic fibrosis. Progr Liver Dis 1990;9:143–55.
   PubMedGoogle Scholar
• Bissell DM. Chronic liver injury, TGF-beta, and cancer. Exp Mol Med 2001;33:179–90.
   PubMedGoogle Scholar
• Friedman SL, Roll FJ, Boyles J, Bissell DM. Hepatic lipocytes: the principal collagen-producing cells of normal rat liver. Proc Natl Acad Sci U S A 1985;82:8681–5.
   PubMed Web of Science ®Google Scholar
• Iredale JP, Benyon RC, Pickering J, McCullen M, Northrop M, Pawley S, Mechanisms of spontaneous resolution of rat liver fibrosis. Hepatic stellate cell apoptosis and reduced hepatic expression of metalloproteinase inhibitors. J Clin Invest 1998;102:538–49.
   PubMed Web of Science ®Google Scholar
• Dienstag JL, Goldin RD, Heathcote EJ, Hann HW, Woessner M, Stephenson SL, Histological outcome during long-term lamivudine therapy. Gastroenterology 2003;124:105–17.
   PubMed Web of Science ®Google Scholar
• Poynard T, McHutchison J, Manns M, Trepo C, Lindsay K, Goodman Z, Impact of pegylated interferon alfa-2b and ribavirin on liver fibrosis in patients with chronic hepatitis C. Gastroenterology 2002;122:1303–13.
   PubMed Web of Science ®Google Scholar
• Iredale JP. Models of liver fibrosis: exploring the dynamic nature of inflammation and repair in a solid organ. J Clin Invest 2007;117:539–48.
   PubMed Web of Science ®Google Scholar
• Ala-Kokko L, Pihlajaniemi T, Myers JC, Kivirikko KI, Savolainen ER. Gene expression of type I, III and IV collagens in hepatic fibrosis induced by dimethylnitrosamine in the rat. Biochem J 1987;244:75–9.
   PubMed Web of Science ®Google Scholar
• Xu G, Niki T, Virtanen I, Rogiers V, De Bleser P, Geerts A. Gene expression and synthesis of fibronectin isoforms in rat hepatic stellate cells. Comparison with liver parenchymal cells and skin fibroblasts. J Pathol 1997;183:90–8.
   PubMedGoogle Scholar
• Serini G, Bochaton-Piallat ML, Ropraz P, Geinoz A, Borsi L, Zardi L, The fibronectin domain ED-A is crucial for myofibroblastic phenotype induction by transforming growth factor-beta1. J Cell Biol 1998;142:873–81.
   PubMed Web of Science ®Google Scholar
• Hynes R. Structure of fibronectins. In: Rich A, editor. Fibronectins. New York: Springer; 1990. p. 113–75.
   Google Scholar
• Matsuura H, Takio K, Titani K, Greene T, Levery SB, Salyan ME, The oncofetal structure of human fibronectin defined by monoclonal antibody FDC-6. Unique structural requirement for the antigenic specificity provided by a glycosylhexapeptide. J Biol Chem 1988; 263:3314–22.
   PubMed Web of Science ®Google Scholar
• Adams LA, Bulsara M, Rossi E, DeBoer B, Speers D, George J, Hepascore: an accurate validated predictor of liver fibrosis in chronic hepatitis C infection. Clin Chem 2005;51:1867–73.
   PubMed Web of Science ®Google Scholar
• Bourliere M, Penaranda G, Adhoute X, Oules V, Castellani P. Combining non-invasive methods for assessment of liver fibrosis. Gastroenterol Clin Biol 2008;32(6 Suppl 1):73–9.
   PubMedGoogle Scholar
• Cales P, Oberti F, Michalak S, Hubert-Fouchard I, Rousselet MC, Konate A, A novel panel of blood markers to assess the degree of liver fibrosis. Hepatology. 2005;42:1373–81.
   PubMed Web of Science ®Google Scholar
• Fontana RJ, Goodman ZD, Dienstag JL, Bonkovsky HL, Naishadham D, Sterling RK, Relationship of serum fibrosis markers with liver fibrosis stage and collagen content in patients with advanced chronic hepatitis C. Hepatology 2008;47:789–98.
   PubMed Web of Science ®Google Scholar
• Forns X, Ampurdanes S, Llovet JM, Aponte J, Quinto L, Martinez-Bauer E, Identification of chronic hepatitis C patients without hepatic fibrosis by a simple predictive model. Hepatology 2002;36(4 Pt 1):986–92.
   PubMedGoogle Scholar
• Giannini E, Risso D, Botta F, Chiarbonello B, Fasoli A, Malfatti F, Validity and clinical utility of the aspartate aminotransferase-alanine aminotransferase ratio in assessing disease severity and prognosis in patients with hepatitis C virus-related chronic liver disease. Arch Intern Med 2003;163:218–24.
   PubMedGoogle Scholar
• Grigorescu M, Rusu M, Neculoiu D, Radu C, Serban A, Catanas M, The FibroTest value in discriminating between insignificant and significant fibrosis in chronic hepatitis C patients. The Romanian experience. J Gastrointestin Liver Dis 2007;16:31–7.
   PubMedGoogle Scholar
• Imbert-Bismut F, Ratziu V, Pieroni L, Charlotte F, Benhamou Y, Poynard T. Biochemical markers of liver fibrosis in patients with hepatitis C virus infection: a prospective study. Lancet 2001;357:1069–75.
   PubMed Web of Science ®Google Scholar
• Leroy V, Halfon P, Bacq Y, Boursier J, Rousselet MC, Bourliere M, Diagnostic accuracy, reproducibility and robustness of fibrosis blood tests in chronic hepatitis C: a meta-analysis with individual data. Clinical Biochem 2008;41:1368–76.
   PubMedGoogle Scholar
• Poynard T, Imbert-Bismut F, Ratziu V, Chevret S, Jardel C, Moussalli J, Biochemical markers of liver fibrosis in patients infected by hepatitis C virus: longitudinal validation in a randomized trial. J Viral Hepat 2002;9:128–33.
   PubMed Web of Science ®Google Scholar
• Pradat P, Alberti A, Poynard T, Esteban JI, Weiland O, Marcellin P, Predictive value of ALT levels for histologic findings in chronic hepatitis C: a European collaborative study. Hepatology 2002;36(4 Pt 1):973–7.
   PubMedGoogle Scholar
• Wai CT, Greenson JK, Fontana RJ, Kalbfleisch JD, Marrero JA, Conjeevaram HS, A simple noninvasive index can predict both significant fibrosis and cirrhosis in patients with chronic hepatitis C. Hepatology 2003;38:518–26.
   PubMed Web of Science ®Google Scholar
• Kisseleva T, Brenner DA. Role of hepatic stellate cells in fibrogenesis and the reversal of fibrosis. J Gastroenterol Hepatol 2007;22Suppl 1:S73–8.
   PubMedGoogle Scholar
• Moreira RK. Hepatic stellate cells and liver fibrosis. Arch Pathol Lab Med 2007;131:1728–34.
   PubMed Web of Science ®Google Scholar
• Oh S, Afdhal NH. Hepatic fibrosis: are any of the serum markers useful? Curr Gastroenterol Rep 2001;3:12–18.
   PubMedGoogle Scholar
• Kawelke N, Bentmann A, Hackl N, Hager HD, Feick P, Geursen A, Isoform of fibronectin mediates bone loss in patients with primary biliary cirrhosis by suppressing bone formation. J Bone Miner Res 2008;23:1278–86.
   PubMedGoogle Scholar
• Bentmann A, Kawelke N, Moss D, Zentgraf H, Bala Y, Berger I, Circulating Fibronectin Affects Bone Matrix While Osteoblast Fibronectin Modulates Osteoblast Function. J Bone Miner Res 2009; in press.
   Google Scholar
• Ishak K, Baptista A, Bianchi L, Callea F, De Groote J, Gudat F, Histological grading and staging of chronic hepatitis. J Hepatol 1995;22:696–9.
   PubMed Web of Science ®Google Scholar
• Group TFMCS. Intraobserver and interobserver variations in liver biopsy interpretation in patients with chronic hepatitis C. Hepatology 1994;20(1 Pt 1):15–20.
   PubMedGoogle Scholar
• Brunt EM. Grading and staging the histopathological lesions of chronic hepatitis: the Knodell histology activity index and beyond. Hepatology 2000;31:241–6.
   PubMed Web of Science ®Google Scholar
• Castera L, Negre I, Samii K, Buffet C. Pain experienced during percutaneous liver biopsy. Hepatology 1999;30:1529–30.
   PubMed Web of Science ®Google Scholar
• McGill DB, Rakela J, Zinsmeister AR, Ott BJ. A 21-year experience with major hemorrhage after percutaneous liver biopsy. Gastroenterology 1990;99:1396–400.
   PubMed Web of Science ®Google Scholar
• Piccinino F, Sagnelli E, Pasquale G, Giusti G. Complications following percutaneous liver biopsy. A multicentre retrospective study on 68,276 biopsies. J Hepatol 1986;2:165–73.
   PubMed Web of Science ®Google Scholar
• Avila JJ, Lympany PA, Pantelidis P, Welsh KI, Black CM, du Bois RM. Fibronectin gene polymorphisms associated with fibrosing alveolitis in systemic sclerosis. Am J Respir Cell Mol Biol 1999;20:106–12.
   PubMedGoogle Scholar
• Bedossa P, Dargere D, Paradis V. Sampling variability of liver fibrosis in chronic hepatitis C. Hepatology 2003;38:1449–57.
   PubMed Web of Science ®Google Scholar
• Bedossa P, Carrat F. Liver biopsy: the best, not the gold standard. J Hepatol 2009;50:1–3.
   PubMed Web of Science ®Google Scholar
• Ziol M, Handra-Luca A, Kettaneh A, Christidis C, Mal F, Kazemi F, Noninvasive assessment of liver fibrosis by measurement of stiffness in patients with chronic hepatitis C. Hepatology 2005;41:48–54.
   PubMed Web of Science ®Google Scholar
• Guha IN, Parkes J, Roderick P, Chattopadhyay D, Cross R, Harris S, Noninvasive markers of fibrosis in nonalcoholic fatty liver disease: Validating the European Liver Fibrosis Panel and exploring simple markers. Hepatology 2008;47:455–60.
   PubMed Web of Science ®Google Scholar